Leeuwenhoek Biotech's presence at BioJapan 2025 will usher in a new chapter in Taiwan-Japan collaboration on intestinal microbiome research.
Leeuwenhoek Laboratories Co., Ltd. participated in BioJapan 2025 (Yokohama), a delegation led by the Ministry of Economic Affairs' Biotechnology and Pharmaceutical Industry Promotion Group (BPIPO, MOEA) and the Center for Biotechnology Development (DCB), representing Taiwan's biotech innovation team. The delegation exhibited its latest R&D results, showcasing Taiwan's strong scientific research capabilities in the fields of intestinal microbiome and precision health.
BioJapan is one of the largest and most internationally influential biotechnology industry exhibitions in Asia, attracting more than 900 manufacturers and nearly 10,000 professionals from around the world to participate every day.Leeuwenhoek, with the theme of "Microbiome × Precision Health," highlighted its biostime product, the patented Akkermansia muciniphila (AKK) strain, and several clinical research results, which can increase GLP-1 secretion in the body. The company also conducted in-depth exchanges and technical cooperation discussions with several Japanese CROs, R&D institutions, consulting firms, and pharmaceutical companies.
During the exhibition, Japanese industry showed growing interest in topics such as gut microbiome and metabolic health, AI-powered precision nutrition, regenerative medicine, and healthy longevity. Leeuwenhoek observed that the Japanese government is actively promoting research clusters and shared laboratory programs in collaboration with hospitals to attract international biotech companies, promote the integration of clinical research and industrial R&D, and gradually build a globally competitive biotech innovation ecosystem.
Leeuwenhoek Marketing Director Hsieh Tung-yu stated that Leeuwenhoek is honored to represent Taiwan on the international stage and to establish a closer collaborative network with Japanese industry. He noted that Japan's extensive experience in clinical research and longevity medicine, combined with Taiwan's strengths in microbiome and metabolome research, will help accelerate the realization of next-generation precision health solutions.
Looking ahead, Leeuwenhoek will continue to prioritize research and deepen its clinical and industry-wide collaborations with Japanese and international partners. Through diverse collaboration models, the company aims to advance applied research in areas such as gut health, metabolic balance, and healthy aging. Together, they aim to develop more precise and safer health products, helping the elderly achieve a science-based vision of "healthy living."
Professor Cheng-Chih Xu, founder and CEO of Leeuwenhoek, said that true innovation comes not only from technological breakthroughs, but also from a long-term commitment to human health. Through close collaboration with Japanese industry, we hope to make scientific findings closer to daily life, allowing consumers around the world to enjoy a healthier and higher-quality life.
Media reports
- Leeuwenhoek Biotech's presence at BioJapan 2025 will usher in a new chapter in Taiwan-Japan collaboration on intestinal microbiome research.
https://news.gbimonthly.com/tw/article/show.php?num=80808
